Showing session: reset
Clinical Trials of New Drugs in Breast Cancer
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer
Maura Dickler
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
C. Kent Osborne
Baylor College of Medicine Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer
Ingrid A Mayer
Vanderbilt University Medical Center, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer
Manish Patel
Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Matthew J. Ellis
Baylor College of Medicine Cancer Ctr., Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer
Patricia LoRusso
Yale, New Haven, CT, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Fabrice Andre
Institut Gustave Roussy, Villejuif, France